Florida Clinical Trials Group.

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Prostate cancer4 trials
• Colorectal cancer3 trials
• Endometrial cancer2 trials
• Gastric and oesophageal cancer2 trials
• Ovarian cancer2 trials
• Head and neck cancer1 trial
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial
• Myeloproliferative neoplasms1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 15 trials
• Phase 33 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Recruiting9 trials
• Not yet recruiting1 trial

Lead sponsor

• Eikon Therapeutics2 trials
• IDEAYA Biosciences2 trials
• Shanghai Henlius Biotech2 trials
• Conjupro Biotherapeutics, Inc.1 trial
• Mirati Therapeutics Inc.1 trial
• and 2 more

Running trials

• Recruiting

  Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

  NCT07777822· Phase 3· Revolution Medicines, Inc.· Source

  Contact: Sandra Perez

• Recruiting

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· Phase 2/3· Eikon Therapeutics· Source

  Contact: Elelta Shiferraw

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

  Contact: Harshad Amin, MD (principal investigator)

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

  Contact: Yinping Zhong

• Recruiting

  A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

  NCT07540572· Phase 1· IDEAYA Biosciences· Source

  Contact: Sandra Perez

• Recruiting

  Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

  NCT07424547· Phase 1· Conjupro Biotherapeutics, Inc.· Source

  Contact: Dr Amin, Principal Investigator

• Recruiting

  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

  NCT07503808· Phase 1· IDEAYA Biosciences· Source

  Contact: Harshad Amin

• Recruiting

  EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  NCT07262619· Phase 1/2· Eikon Therapeutics· Source

  Contact: Ana C Mamede, PharmD

• Recruiting

  Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

  NCT07176650· Phase 1· Shanghai Henlius Biotech· Source

  Contact: Henlius

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

  Contact: Harshad Amin, Site 0365

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Prostate cancer4 recruiting
• Colorectal cancer3 recruiting
• Endometrial cancer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Ovarian cancer2 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Triple-negative breast cancer1 recruiting